PATENT RIGHTS Coverage. In the event that (i) COMPANY or its SUBLICENSEES sell a LICENSED PRODUCT in a country where no PATENT RIGHTS are issued and no patent applications that are part of the PATENT RIGHTS are pending that have not been pending for less than [**] years after filing national patent applications in the country in question, and (ii) such LICENSED PRODUCT is manufactured in a country where PATENT RIGHTS are issued or patent applications that are part of the PATENT RIGHTS are pending that have not been pending for more than [**] years after filing national patent applications in the country in question, the royalties stated in Section 5.2 will be reduced by [**]% ([**] percent) for such LICENSED PRODUCT, until the expiration or abandonment of all issued patents and filed patent applications within the PATENT RIGHTS in the country in which the LICENSED PRODUCT is manufactured.
Appears in 7 contracts
Sources: Collaboration Agreement (Alnylam Pharmaceuticals, Inc.), Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.), Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals Inc)
PATENT RIGHTS Coverage. In the event that (i) COMPANY or its SUBLICENSEES sell a LICENSED PRODUCT in a country where no PATENT RIGHTS are issued and no patent applications that are part of the PATENT RIGHTS are pending that have not been pending for less than [**] years after filing national patent applications in the country in question, and (ii) such LICENSED PRODUCT is manufactured in a country where PATENT RIGHTS are issued or patent applications that are part of the PATENT RIGHTS are pending that have not been pending for more than [**] years after filing national patent applications in the country in question, the royalties stated in Section 5.2 will be reduced by [**]% ([**] ]percent) for such LICENSED PRODUCT, until the expiration or abandonment of all issued patents and filed patent applications within the PATENT RIGHTS in the country in which the LICENSED PRODUCT is manufactured.
Appears in 3 contracts
Sources: Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.), Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.), Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)
PATENT RIGHTS Coverage. In the event that (i) COMPANY or its SUBLICENSEES sell a LICENSED PRODUCT in a country where no PATENT RIGHTS are issued and no patent applications that are part of the PATENT RIGHTS are pending that have not been pending for less than [***] years after filing national patent applications in the country in question, and (ii) such LICENSED PRODUCT is manufactured in a country where PATENT RIGHTS are issued or patent applications that are part of the PATENT RIGHTS are pending that have not been pending for more than [***] years after filing national patent applications in the country in question, the royalties stated in Section 5.2 will be reduced by [***]% ([***] percent) for such LICENSED PRODUCT, until the expiration or abandonment of all issued patents and filed patent applications within the PATENT RIGHTS in the country in which the LICENSED PRODUCT is manufactured.
Appears in 1 contract
Sources: Strategic Collaboration and License Agreement (Isis Pharmaceuticals Inc)